Lilly forecasts weak fourth-quarter sales of weight-loss drug, shares slump
Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street estimates in the fourth quarter, sending the drugmaker's shares down more than 8% on Tuesday.
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
7 facts about this weight loss drugs that actually work
Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know about these game-changing medications.
Eli Lily cuts 2024 revenue guidance by $400M, shares sink 8%
The company expects Q4 2024 revenue of approximately $13.5 billion. The updated revenue guidance is $400 million lower than previously shared.
Eli Lilly Stock Falls on Slower Sales Growth of Anti-Obesity Drugs
Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for diabetes drug Mounjaro and $1.
Lilly Forecasts Weak Sales of Weight-Loss Drug in Fourth Quarter
(Reuters) - Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecast 2025 revenue largely above estimates.
Eli Lilly's weight loss pill could get federal approval by early next year
Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks told Bloomberg News on Monday that data on the drug, orforglipron, is expected before the middle of 2025.
Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...
Insider Monkey6h
Why Eli Lilly (LLY) Stock Is Declining Today
Eli Lilly blamed the shortfall on lower-than-anticipated demand for its weight-loss drugs. Indeed, the drug maker estimated ...
Obesity rate drops in the U.S., healthcare experts point to GLP-1 medications as the cause
For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that from 2021 to 2023, those rates dropped from 41.9% to 40.3%.
Hosted on MSN2h
What is Mounjaro? Everything to know about NHS approved weight loss jab
One jab that's been capturing public attention and headlines lately is Mounjaro. The Labour Party unveiled plans to ...
What's in the 'Natural Mounjaro' Drink — and Should You Try It?
"We're suckers for quick fixes," Emily Feivor, a registered dietician, tells PEOPLE about the claim that honey, lemon, water, ...
Ozempic and Mounjaro increase weight loss. These nutritionist-backed tricks have the same miraculous effect
Ozempic and Mounjaro increase weight loss. These nutritionist-backed tricks have the same miraculous effect - Weight loss ...